GWA 106

GWA 106 is a small molecule drug candidate developed by Gongwin Biopharm specifically for the treatment of equine tumors. It is part of the company's proprietary Para-Toluenesulfonamide (PTS) platform, which focuses on small molecule drugs that exhibit selective necrotizing effects on cancer cells. The mechanism of action for GWA 106 involves the dual targeting of lysosomes and mitochondrial ATP synthase. By disrupting these critical cellular components, the drug impairs energy production and triggers cell death within the tumor microenvironment. While other compounds in the PTS series are being developed for human indications such as lung and liver cancer, GWA 106 is positioned within Gongwin's veterinary pipeline to address oncological needs in horses.